Gabil

Quick links to important sections

Gabil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gabil

Quick Facts

Property Description
Active Ingredients Gabapentin, Mecobalamin
Form & Status Fixed-Dose Combination Oral Tablet; Prescription Only (Rx)
Pharmacological Class Anticonvulsant, Vitamin (B12)
General Purpose Stabilizing nerve activity and supporting nerve regeneration
Manufacturer Biocon (India)

Gabil: Definition and Classification as a Combination Drug

Gabil is a fixed-dose combination drug available as an oral tablet that incorporates two distinct active ingredients: the synthetic agent Gabapentin and the essential nutrient Mecobalamin (Methylcobalamin). As a prescription-only medication often manufactured by companies like Biocon, Gabil targets two separate aspects of nerve health simultaneously. Gabapentin is classified as a gamma-aminobutyric acid analogue and anticonvulsant, while Mecobalamin is categorized as a bioavailable Vitamin B12 analogue within the group of antianemic preparations.


The Dual Nature of Gabapentin and Mecobalamin

The components of Gabil work through distinct mechanisms. Gabapentin is recognized for its ability to modulate nerve signaling by interacting with the alpha2delta protein subunit of voltage-gated calcium channels on nerve cells. Mecobalamin, a derived coenzyme form of Vitamin B12, is involved in nerve metabolism, supporting the synthesis of the myelin sheath that protects nerve fibers. This specific choice of Mecobalamin, instead of forms like Cyanocobalamin, is a differentiating factor in the combination's therapeutic design, emphasizing neuroregenerative support.


General Purpose: Stabilizing Nerves and Supporting Regeneration

The overall utility of Gabil is to address nerve dysfunction through its dual-action capability. The formulation is intended to modulate signaling in overactive nerve pathways while simultaneously providing metabolic support required for nerve maintenance and repair. Gabapentin functions as an agent for modulating nerve activity and reducing discomfort. This combined effort aims to address the hyperexcitability associated with certain sensations and support the body’s mechanisms for maintaining nerve integrity.

Regulatory References

  1. Vitamin B12 and Myelination (NIH PMC)
  2. Gabapentin Drug Information - MedlinePlus

What side effects are possible with Gabil?

Possible Side Effects and Safety Information

The officially documented safety profile for Gabil, a combination drug, is largely determined by its component Gabapentin. The potential adverse reactions are classified by regulatory bodies based on frequency, with effects on the Nervous System being the most frequently reported.

Classification Examples of Officially Documented Effects
Very Common Dizziness, Somnolence (Drowsiness).
Common Ataxia (unsteadiness), Fatigue, Peripheral Edema (swelling), Weight increase, Headache, Nausea, Vomiting, Diplopia (double vision).

The most frequent effects, such as dizziness and somnolence, are often noted in regulatory documents to be more common at the start of treatment or during dose increases. Abruptly stopping Gabapentin-containing medications may also precipitate seizures or status epilepticus, necessitating a gradual discontinuation process.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights severe, though rare, safety risks, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a potentially life-threatening multi-organ hypersensitivity reaction. Furthermore, a class-wide warning for Suicidal Ideation and Behavior is documented, consistent with other anti-epileptic drugs.

Safety constraints also address the drug’s elimination: because Gabapentin is primarily cleared by the kidneys, official documents stipulate that a mandatory dose adjustment is required for individuals with renal impairment. The CNS effects are also more pronounced in older adults, which can contribute to an increased risk of accidental injury, such as falls.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to the Gabapentin component of Gabil is primarily characterized by Central Nervous System (CNS) depression. Documented clinical manifestations of overdose include slurred speech (dysarthria), ataxia (impaired coordination), lethargy, drowsiness, nystagmus, and diplopia. While high acute overexposures have been documented, severe manifestations typically involve the respiratory system.


Urgent Medical Attention Required

Regulators explicitly warn that overdose carries the risk of respiratory depression, coma, and death, particularly when the drug is taken concomitantly with other CNS depressants, such as Opioids. Immediate medical attention must be sought if signs of respiratory problems occur, including severe sleepiness, confusion, or difficulty breathing. If a person is unresponsive or loses consciousness, emergency medical services must be contacted immediately.


Management and Risk Considerations

No specific antidote is known for Gabapentin overexposure; management involves symptomatic and supportive treatment and close observation. Hemodialysis may be considered for severe cases, especially in patients with renal impairment. Individuals who are elderly or have pre-existing respiratory or neurological disease are noted to be at a higher risk for severe adverse reactions.

Therapeutic Uses of Gabil

What Gabil Treats: Main Uses and Benefits

The Gabapentin/Mecobalamin combination is commonly used to help manage neuropathic pain, a type of pain relevant in conditions where functional stability becomes affected. The medication is indicated for addressing the symptoms related to physical discomfort of chronic neuropathic pain.

Common clinical scenarios for its use include conditions characterized by periods of heightened symptoms, such as Diabetic Peripheral Neuropathy (nerve damage from diabetes) and Postherpetic Neuralgia (persistent pain after shingles). It is applied in addressing symptom clusters that may become intense or disruptive, like shooting, stabbing, or burning pain, as well as uncomfortable tingling and prickling sensations. This approach supports general well-being during symptomatic phases and is relevant for managing symptoms that interfere with daily comfort.

“The combination is considered relevant for managing symptoms that create noticeable functional strain related to nerve damage.”


Quick Fact: Supportive Management for Neuropathic Symptoms Property Description
Primary Therapeutic Area Chronic Neuropathic Pain
Symptoms Addressed Shooting, burning, and tingling nerve pain
Clinical Contexts Diabetic Neuropathy, Postherpetic Neuralgia
Patient Benefit Assists with maintaining functional stability and contributes to easing the overall symptom load

Regulatory References

  1. official drug characteristics document (NAFDAC)

Eligibility and Restrictions for Use

Official Population Eligibility for Gabil

This section outlines the eligibility and non-eligibility requirements for Gabil (Gabapentin/Mecobalamin) as documented in official government regulatory labels.

Absolute Contraindications

Use of Gabil is contraindicated and prohibited for any patient with a known hypersensitivity to Gabapentin, Mecobalamin, or any other component in the formulation. Treatment must also not be restarted in individuals with a prior history of Severe Cutaneous Adverse Reactions (SCARs), such as DRESS, linked to Gabapentin use.

Restricted and Conditional Use

Population Group Regulatory Status
Renal Impairment Conditional Use; mandatory dose adjustment is required due to Gabapentin's elimination pathway. Use may be prohibited in severe impairment ( CrCl < 30 mL/min).
Older Adults (ge 65) Conditional Use; monitoring and dose adjustment may be necessary due to age-related decline in kidney function.
Pediatric Patients Not Established for the neuropathic pain indication; safety and effectiveness have not been confirmed in patients under 18 years.
Pregnancy/Lactation Restricted Use; generally not recommended unless the treating physician determines the clinical benefit clearly outweighs the potential risk to the fetus or infant.

The official profile restricts use based on physiological constraints, especially compromised renal function, and allergy history. Use is generally established for adults but is constrained by a lack of efficacy data for neuropathic pain in the pediatric population.

What should I know about interactions with other medicines?

Gabil Interactions with other medicines and products

The official interaction profile for Gabil (Gabapentin/Mecobalamin) is structured around specific pharmacodynamic risk and altered drug exposure, as documented by regulatory authorities.


Pharmacodynamic and Exposure Interactions

Co-administration with opioid analgesics carries a documented risk of serious, life-threatening respiratory depression and additive CNS depression. Other central nervous system depressants, such as anxiolytics and muscle relaxers, also pose an elevated risk of somnolence and sedation. Certain medicines modify Gabapentin exposure: co-administration with Morphine or Hydrocodone is officially documented to increase Gabapentin plasma concentration (AUC). Gabapentin is not appreciably metabolized and does not interfere with the metabolism of other co-administered antiepileptic medicines.


Absorption and Timing Rules

Interactions affecting absorption are documented for both components. The concurrent use of antacids containing aluminum or magnesium reduces Gabapentin absorption. To mitigate this effect, official regulatory documents require Gabapentin to be administered at least two hours following antacid ingestion. For the Mecobalamin component, long-term use of gastric acid inhibitors (e.g., Proton Pump Inhibitors) and the medicine Metformin are officially stated to potentially lower Vitamin B12 serum levels. Alcohol must be avoided due to the documented increase in CNS depressant effects.

Mechanism of Action

Pharmacodynamic Mechanism

Modulating Neuronal Hyperexcitability

Gabapentin achieves its action by binding specifically to the alpha2delta-1 protein subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs). This binding acts as an allosteric modulator, which reduces the functional density of these channels on the nerve terminal membrane. The consequence is a decreased calcium ion influx into the presynaptic space, leading to a subsequent reduced release of excitatory neurotransmitters (e.g., glutamate). This cascade dampens overactive nerve impulse transmission, which is a key physiological process in modulating signal transduction within the nervous system.

Metabolic Assistance for Structural Integrity

The second component, Mecobalamin, acts as a vital coenzyme for the enzyme Methionine Synthase within the fundamental methylation cycle. By facilitating this metabolic pathway, Mecobalamin enhances the availability of compounds necessary for the synthesis of structural lipids and proteins. This physiological assistance is required for the creation of the nerve's myelin sheath and the overall axonal structure, which contributes to the integrity and functional capacity of the nerve fibers.

Complementary Mechanisms

The two components provide complementary mechanisms: Gabapentin provides functional signal modulation to reduce electrical over-activity, while Mecobalamin provides the metabolic resources necessary for structural components. This combined mechanism addresses both signal control and the underlying structural integrity of the nerve pathways.

Dosage and Administration Information

How Gabil is Used: General Administration Standards

The usage of the Gabapentin/Mecobalamin combination drug, Gabil, follows established protocols concerning its route, dosing schedule, and procedural adjustments. The medication is for oral use via the tablet form.

Dosing Schedule and Titration

Therapy typically does not begin at the full amount; instead, a titration scheme is utilized. The dose of the Gabapentin component is introduced gradually, starting with a small dose (such as 300 mg) on the first day and increasing stepwise over the subsequent days.

The final adult maintenance dosage range is generally 900 mg to 3600 mg per day in the Gabapentin component, depending on the clinical scenario. The full daily amount is administered in three equally divided doses (TID). To ensure sustained availability, the interval between any two doses is designed not to exceed 12 hours.


Administration Conditions and Special Adjustments

For practical administration, the Gabil tablet may be taken with or without food. However, the tablet is intended to be swallowed whole with liquid and should not be crushed, broken, or chewed. Taking the drug involves specific timing relative to antacids: it is administered at least two hours following the use of any aluminum- or magnesium-containing antacids.

For specific populations, dose adjustment is a clinical requirement for adult patients exhibiting renal impairment (reduced kidney function), as the dosage is dependent on the patient's measured Creatinine Clearance.


Discontinuation Protocol

Treatment with Gabil is not concluded abruptly. When discontinuation is necessary, the dose is gradually reduced over a minimum period of at least one week (tapering) to adhere to procedural clinical standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gabil

Evidence for Use in Neuropathic Pain

Research examining the components of Gabil in the setting of chronic neuropathic pain has primarily relied on short-term, randomized, placebo-controlled trials. These studies were used in research exploring how symptoms change over time by measuring patient-reported outcomes describing perceived discomfort, specifically focusing on changes in daily pain scores and the proportion of participants reporting a specified threshold of change in pain. Research describes the use of Gabil’s components in conditions where symptoms may vary in intensity.

Findings describe patterns observed in the studies over the relatively short observation intervals. Some trials described a pattern where participants reported changes in pain intensity that coincided with the study period when the drug's components were used, when compared to groups receiving an inactive substance (placebo). Studies monitored outcomes related to physical discomfort and pain-related sleep interference in these trials. However, follow-up durations were limited in these key controlled studies, meaning that the findings help contextualize how patients reported their experience only for the initial treatment period.


Evidence for Use in Fibromyalgia

Research has explored the components of Gabil in fibromyalgia, a condition marked by functional limitations and widespread pain. Research in this area has primarily involved short-term, randomized, placebo-controlled trials. Outcomes measured included various outcomes reflecting daily functioning or activity level, including changes in pain severity, fatigue, and standardized scores used to measure the overall impact of fibromyalgia.

Studies monitored changes during research exploring short-term symptom changes, typically lasting only a few months. Research highlights changes measured during the study period in patient-reported levels of pain and fatigue. However, sample sizes were modest in some of the initial studies, and the available evidence is limited when examining long-term consistency.


What is Still Uncertain About Gabil's Research

The available research indicates that certainty remains low regarding the long-term findings across all patient groups and indications. Long-term effects are not fully established by controlled studies, and continued research is needed to understand outcomes over many years. Evidence is limited in terms of direct, randomized comparisons between Gabil’s two components across all conditions. These limitations mean that the findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

  1. Pharmacological treatment of neuropathic pain in adults: a systematic review and guideline update
  2. Clinical Guideline: Pharmacological management of chronic pain in adults (NICE Guideline NG193)

Frequently Asked Questions (FAQ)

Common questions about Gabil (FAQ)

Q: What specific medical uses is Gabil approved for by regulatory bodies?

Official regulatory bodies typically approve the component Gabapentin for managing Postherpetic Neuralgia, which is nerve pain following a shingles outbreak. It is also approved as an add-on treatment for certain types of partial onset seizures. The specific approved indications for the combination product Gabil may vary depending on the country's local regulatory guidelines.


Q: Is Gabil a controlled substance in the country I live in?

According to US federal regulations, the Gabapentin component is not classified as a controlled substance. However, several US states classify Gabapentin as a Schedule V controlled substance, which means it has the lowest potential for abuse among scheduled drugs but requires stricter monitoring. It is important to check the classification where you live, as regulations can vary by state or country.


Q: Can Gabil cause long-term side effects on memory or concentration?

Memory difficulties and changes in concentration are reported as possible side effects. While regulatory documents note that the long-term effects of Gabil are not fully established by controlled studies, monitoring for persistent cognitive issues is described in the official guidance. Individuals who note new or worsening memory problems while taking Gabil may wish to consult their healthcare provider.


Q: Are there any serious side effects of Gabil that require immediate medical attention?

Official labeling highlights severe, though rare, safety risks, including a life-threatening rash known as DRESS and a class-wide warning for Suicidal Ideation and Behavior. Official documents describe signs of serious central nervous system depression that should be noted, especially when Gabil is taken with opioid medications. If any severe symptoms are observed, seeking urgent medical care is specified in the safety information.


Q: Can Gabil usage lead to changes in mood or feelings of nervousness?

Yes, anxiety and other psychological effects are reported as possible side effects when taking this type of medication. Furthermore, the official labeling includes a class-wide warning regarding the rare, but serious, risk of Suicidal Ideation and Behavior. Official guidance recommends that any new or worsening changes in mood or behavior be discussed with a healthcare professional.


Q: Are there reported interactions between Gabil and over-the-counter pain relievers?

Official drug information does not list any known clinically significant interactions between the Gabil component and common non-opioid, over-the-counter (OTC) pain relievers like ibuprofen or acetaminophen. It is important to discuss all medications and supplements, including OTC products, with a pharmacist or doctor.


Q: Does Gabil interact with commonly prescribed antidepressant medications?

Yes, the Gabapentin component may interact with certain antidepressant medications. This combination can increase the risk of central nervous system side effects such as enhanced drowsiness or dizziness. Specific guidance on concurrent use with CNS depressants is provided in the regulatory labeling.


Q: Are there specific food types or beverages that are known to interact with Gabil?

Regulatory documents state that Gabil tablets can be taken either with or without food. The main rule related to ingestion is that Gabil must be taken at least two hours after consuming any aluminum- or magnesium-containing antacids to prevent reduced absorption. No specific foods or beverages other than alcohol are generally listed as having clinically significant interactions.


Q: Can Gabil affect the function or effectiveness of oral birth control pills?

Studies reviewed by regulatory bodies confirm that the Gabapentin component in Gabil does not affect the function or effectiveness of common oral contraceptives. Therefore, it is considered unlikely to cause a failure in contraception.


Q: What is the risk of interaction between Gabil and common herbal supplements or vitamins?

Official regulatory bodies advise general caution when combining Gabil with herbal remedies or other supplements. This is especially important for supplements that can cause sedation, as combining them with Gabil may increase side effects like dizziness or drowsiness.


Q: Does Gabil pass into breast milk when a mother is breastfeeding?

Yes, studies confirm that the Gabapentin component is secreted into human milk. The official label describes that Gabil use is generally reserved for cases where the potential benefit is determined to outweigh the risk to the infant. Monitoring infants for potential effects like drowsiness or difficulties with weight gain is recommended in the prescribing information.


Q: Are there restrictions on Gabil use for people with pre-existing kidney or liver problems?

Dose adjustment is mandatory for patients with reduced kidney function (renal impairment) because Gabapentin is cleared from the body primarily by the kidneys. Patients with low kidney function may need a significantly reduced dose to prevent side effects. Official regulatory information does not typically list specific dose restrictions for pre-existing liver problems.


Q: Is a history of depression or mood disorders a factor in Gabil eligibility?

Official labeling includes a class-wide warning about the risk of Suicidal Ideation and Behavior associated with this class of drugs. Due to this risk, prescribers are generally advised to assess a patient's mental health history, including any history of depression or mood disorders, both before starting and during treatment with Gabil.


Q: How long does it usually take for a person to notice the intended effects of Gabil?

According to summaries of clinical data, therapeutic effects for conditions like nerve pain may begin to be noticeable as early as two weeks after initiating Gabil. However, the full benefit of the medication can take a longer period of time, as the dose is often gradually increased.


Q: Is Gabil a medication intended for short-term use, or is it typically taken long-term?

Gabil is often used for chronic conditions, implying long-term therapy. However, regulatory advisories suggest using the lowest effective dose for as short a period as possible, as long-term effects over many years are not fully established by controlled studies. The mandatory gradual reduction (tapering) protocol is designed for patients who have been taking the medication for an extended time.


Q: What should be done if a patient feels no different after taking Gabil for a few weeks?

Official guidance advises that if a patient feels no benefit from Gabil after a few weeks, they should consult their healthcare provider. This is because the medication may take time to reach its full effect as the dose is gradually adjusted. Official guidance specifies that any dose adjustments should occur under the direction of a qualified physician.


Q: Is the brand name version of Gabil medically interchangeable with its generic equivalent?

Regulatory bioequivalence studies generally indicate that generic formulations of the Gabapentin component are medically interchangeable with the brand name. Nevertheless, some national regulatory agencies advise caution or monitoring when switching between different formulations for individual patients.


Q: What happens in the body when Gabil is stopped suddenly after long-term use?

Official warnings describe that abruptly stopping Gabil after long-term use may precipitate seizures or status epilepticus. Other discontinuation symptoms such as increased anxiety, insomnia, nausea, or pain may also occur. A gradual reduction (tapering) over at least one week is specified in the discontinuation protocol to minimize these risks.


Q: Why are there different strengths and forms (e.g., tablet, capsule) of Gabil available?

Different tablet strengths are necessary to accommodate the mandatory dose titration, which is the gradual increase in dosage at the start of treatment. These various strengths also allow physicians to make the mandatory dose adjustments required for patients who have reduced kidney function.


Q: Can Gabil cause withdrawal symptoms if the medication is discontinued?

Yes, official information confirms that withdrawal symptoms have been reported after stopping Gabil. These symptoms can include anxiety, insomnia, headache, nausea, and diarrhea. Official guidance emphasizes that the medication should be discontinued gradually, as a sudden stop has been associated with withdrawal symptoms. A gradual dose reduction (tapering) protocol is outlined in the product information.

How should Gabil be stored and disposed of?

How to Store and Dispose of Gabil?

This information is based on official regulatory labeling regarding storage, stability, and disposal requirements.

Official Storage Requirements

Requirement Official Statement
Temperature Store at controlled room temperature, 20 C to 25 C. Do not freeze.
Protection Keep in the original container to protect from light and moisture.
Child Safety Keep out of the sight and reach of children.

Stability and Handling

Stability instructions mandate that the container must be kept tightly closed. If Gabil is a product requiring reconstitution, the official label specifies that the prepared solution must be used within 24 hours when stored under refrigerated conditions (2 C to 8 C).

Disposal of Unused Medicine

Official disposal requirements prohibit discarding Gabil in household waste or wastewater (flushing). Unused or expired medication must be handled according to local environmental regulations, typically by returning the product to a pharmacy or an authorized governmental take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gabil found in:

A-Z Index: